Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 397-398

  Trautmann, Karolin ^a   Jakob, Christiane ^a   von Grünhagen, Ulrich ^b   Schleyer, Eberhard ^c   Brümmendorf, Tim H ^d   Siegert, Gabriele ^a   Ehninger, Gerhard ^a   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Oncology Practice   (Germany)

^c Carl von Basedow Clinic   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; THROMBOPOIETIN;

ADOLESCENT; ADULT; BLACKFAN DIAMOND ANEMIA; BONE MARROW BIOPSY; BONE MARROW HYPOPLASIA; CASE REPORT; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DYSKERATOSIS CONGENITA; FEMALE; HUMAN; HUMAN TISSUE; LETTER; MALE; MEGAKARYOCYTE; PANCYTOPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANEMIA, DIAMOND-BLACKFAN; BENZOATES; CARDIOLOGY; DYSKERATOSIS CONGENITA; FEMALE; HUMANS; HYDRAZINES; MALE; MEGAKARYOCYTES; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84870341588     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-02-0121     Document Type: Letter

References (12)

1. Pecci A, Gresele P, Klersy C et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116: 5832-5870.
2. Grôpper S, Althaus K, Najm J et al. A patient with Fechtner syndrome successfully treated with romi-plostim. Thromb Haemost 2012; 107: 590-591.
3. Pecci A, Barozzi S, d'Amico S et al. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. Thromb Haemost 2012; 107:1188-1189.
4. Olnes MJ, Scheinberg P, Calvo K et al. Eltrombopag can stimulate trilineage hematopoiesis with transfusion independence in patients with refractory severe aplastic anemia: results from a phase II trial. Blood (Annual Meeting Abstracts), 2011; 118: 54.
5. Jenkins JM, Williams D, Deng Y et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-4741.
6. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am 2009; 23: 261-282.
7. Freedman M.H. Inherited Forms of Bone Marrow Failure. In: Hematology: Basic Principles and Practice. Elsevier, 2005
8. Du HY, Pumbo E, Ivanovich J et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009; 113: 309.
9. Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-re-lated inherited thrombocytopenias. Br J Hematol 2011; 154: 161-174.
10. Pecci A, Malara A, Badalucco S et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009; 102: 90-96.
11. Nurden P, Nurden AT. Congenital disorders associated with platelet dysfuncions. Thromb Haemost 2008; 99: 253-263.
12. Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35: 189-203.